STUTTGART, Germany, January 14, 2016 /PRNewswire/ --
A long-term follow-up study with case-control comparison was recently published by the International Journal of Cardiology (link). In the study, chronic heart failure patients receiving CCM™ therapy showed significantly improved long-term survival when compared to matched patients who did not receive the therapy.
(Photo: http://photos.prnewswire.com/prnh/20160114/322199 )
In the reported analysis, 41 heart failure patients who received CCM were followed for about 6 years, and compared with a matched group of 41 heart failure patients derived from a registry in the same hospital. The primary end-point, all-cause mortality, was significantly lower in the CCM group than in the control group. In the subgroup of subjects with baseline ejection fraction between 25% and 40%, but not in the general cohort, heart failure hospitalizations were significantly lower with CCM therapy.
CCM therapy, or cardiac contractility modulation, is delivered by Impulse Dynamics’ innovative Optimizer™ IVs, a minimally invasive implantable device for treatment of chronic heart failure. “Our product offers new hope for the many patients suffering from heart failure and their families,” said Dr. Simos Kedikoglou, CEO of Impulse Dynamics. “The new data supplements the growing body of evidence on the safety of our novel therapy and its effects on quality of life and exercise capacity in heart failure patients.”
About the Optimizer and CCM Therapy
The Optimizer IVs device which delivers CCM therapy has been successfully launched in Europe and other international markets and is available in a growing number of cardiology centers around the world. The therapy has been implanted in about 3,000 patients to date and is the only device therapy available for patients with narrow QRS complex. Impulse Dynamics has completed a vast number of clinical studies, including several randomized controlled trials, as published in over 60 publications in leading medical journals. The Optimizer IVs is limited to investigational use in the USA.
About Impulse Dynamics
Impulse Dynamics N.V., a member of the Hobart Group companies, is focused on the development of electrical therapies for the treatment of chronic heart failure. As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the US, Europe, Asia and Australia. For more information please visit http://www.impulse-dynamics.com
About the Hobart Group
The Hobart Group accelerates ideas and develops and commercializes medical technologies, targeting top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the fields of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies employ over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from the group’s financial strength, clinical expertise and extensive international market knowledge across Europe, the US and Asia. For more information please visit http://www.hobart-group.com
CCM and Optimizer are trademarks of Impulse Dynamics N.V.
Media Inquiries
Mrs. Sharon Alon
Email: Media@impulse-dynamics.com
Tel: +1-347-566-6113
SOURCE Impulse Dynamics
